Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer.
作者信息
Mao C, Liao R-Y, Chen Q
出版信息
Br J Cancer. 2010 Mar 2;102(5):940. doi: 10.1038/sj.bjc.6605575. Epub 2010 Feb 16.
Abstract
摘要
相似文献
1
Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer.
Br J Cancer. 2010 Mar 2;102(5):940. doi: 10.1038/sj.bjc.6605575. Epub 2010 Feb 16.
2
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287.
3
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.
Expert Opin Biol Ther. 2009 May;9(5):565-77. doi: 10.1517/14712590902870394.
4
Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
Clin Colorectal Cancer. 2004 Sep;4(3):159-62. doi: 10.1016/s1533-0028(11)70113-x.
5
PTEN status in advanced colorectal cancer treated with cetuximab.
Br J Cancer. 2010 Jan 5;102(1):162-4. doi: 10.1038/sj.bjc.6605471. Epub 2009 Dec 1.
6
Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
Recent Pat Anticancer Drug Discov. 2010 Jun;5(2):142-51. doi: 10.2174/157489210790936270.
7
Panitumumab a novel drug in cancer treatment.
Ann Oncol. 2007 Jun;18 Suppl 6:vi16-21. doi: 10.1093/annonc/mdm218.
8
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Cancer Res. 2008 Mar 15;68(6):1953-61. doi: 10.1158/0008-5472.CAN-07-5659.
9
Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with p.G13D Mutation.
Int J Mol Sci. 2020 Aug 21;21(17):6037. doi: 10.3390/ijms21176037.
10
BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer.
J Cancer Res Clin Oncol. 2010 Aug;136(8):1293-4. doi: 10.1007/s00432-010-0922-8. Epub 2010 Jun 1.
引用本文的文献
1
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study.
Cancer Res Treat. 2023 Jul;55(3):841-850. doi: 10.4143/crt.2022.1438. Epub 2023 Feb 13.
2
Evaluating the value of Amphiregulin, Phosphatase and Tensin Homologue (PTEN) and P21 Expression for Anti-EGFR Treatment in Metastatic Colorectal Carcinoma.
Asian Pac J Cancer Prev. 2021 Apr 1;22(4):1025-1034. doi: 10.31557/APJCP.2021.22.4.1025.
3
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.
Cancers (Basel). 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214.
4
Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.
5
Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.
Transl Oncol. 2019 Mar;12(3):502-512. doi: 10.1016/j.tranon.2018.12.003. Epub 2018 Dec 27.
6
Biomarker threshold adaptive designs for survival endpoints.
J Biopharm Stat. 2018;28(6):1038-1054. doi: 10.1080/10543406.2018.1434191. Epub 2018 Feb 13.
7
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.
Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17.
8
EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis.
Medicine (Baltimore). 2017 Feb;96(7):e6151. doi: 10.1097/MD.0000000000006151.
9
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.
Chin J Cancer. 2015 Apr 8;34(4):149-60. doi: 10.1186/s40880-015-0007-9.
10
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.
Drugs. 2015 May;75(7):731-48. doi: 10.1007/s40265-015-0386-x.
本文引用的文献
1
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27.
2
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.
Br J Cancer. 2009 Apr 7;100(7):1087-94. doi: 10.1038/sj.bjc.6604848. Epub 2009 Mar 17.
3
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.
4
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
Br J Cancer. 2007 Oct 22;97(8):1139-45. doi: 10.1038/sj.bjc.6604009. Epub 2007 Oct 16.
Zotero 插件